Stealth Peptides Inc. Completes Initial Phase I Clinical Trial Cohort with BendaviaTM, a Mitochondrial Targeted Therapy for Ischemia Reperfusion Injury

ROCKVILLE, Md.--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative therapies, announced today that it concluded its initial Phase I clinical trial cohort of a first–in–humans study with Bendavia™, a compound that targets mitochondria to treat ischemia reperfusion injury. The Investigational New Drug (IND) application for Bendavia was approved by the U.S. Food and Drug Administration (FDA) during May 2010.